Low-dose daunorubicin in induction treatment of childhood acute lymphoblastic leukemia: No long-term cardiac damage in a randomized study of the Dutch childhood leukemia study group

Medical and Pediatric Oncology

Volumn 35, Issue 1, 2000, Pages 13-19

  Rammeloo, L A J ^a   Postma, A ^a,c,d   Sobotka Plojhar, M A ^b   Bink Boelkens, M Th E ^a   Vd Does Vd Berg, A ^c   Veerman, A J P ^b,c   Kamps, W A ^a,c  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Dutch Childhood Leukemia Study Group   (Netherlands)

^d Children's Cancer Center Groningen   (Netherlands)

Author keywords

Acute lymphoblastic leukemia; Cardiac damage; Daunorubicin; Long term effects

Indexed keywords

ASPARAGINASE; DAUNORUBICIN; PREDNISONE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CHILDHOOD CANCER; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLE; ELECTROCARDIOGRAM; FEMALE; HEART ARRHYTHMIA; HEART LEFT VENTRICLE CONTRACTION; HEMODYNAMICS; HUMAN; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTIBIOTICS, ANTINEOPLASTIC; DAUNORUBICIN; DRUG ADMINISTRATION SCHEDULE; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; FEMALE; HEART DISEASES; HEART RATE; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE; MALE; PILOT PROJECTS; REMISSION INDUCTION; SURVIVORS;

EID: 0033919129     PISSN: 00981532     EISSN: None     Source Type: Journal    
DOI: 10.1002/1096-911X(200007)35:1<13::AID-MPO3>3.0.CO;2-G     Document Type: Article

References (42)

1. Goorin AM, Chauvenet AR, Perez-Atayde AR, et al. Initial congestive heart failure, six to ten years after doxorubicin chemotherapy for childhood cancer. J Pediatr 1990;116:144-147.
2. Lipshultz SE, Colan SD, Gelber RD, et al. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 1991;324:808-815.
3. Steinherz LJ, Steinherz P, Tan CTC, et al. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 1991;266: 1672-1677.
4. Lipshultz SE, Lipsitz SR, Mone SM, et al. Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med 1995;332:1738-1743.
5. Sorensen K, Levitt G, Sebag-Montefiore D, et al. Cardiac function in Wilms' tumor survivors. J Clin Oncol 1995;13:1546-1556.
6. Minow RA, Benjamin RS, Lee ET, et al. Adriamycin cardiomyopathy-risk factors. Cancer 1977;39:1397-1402.
7. Sorensen K, Levitt G, Bull C, et al. Anthracycline dose in childhood acute lymphoblastic leukemia: Issues of early survival versus late cardiotoxocity. J Clin Oncol 1997;15:61-68.
8. Giantris A, Abdurrahman L, Hinkle A, et al. Anthracycline-induced cardiotoxicity in children and young adults. Crit Rev Oncol Hematol 1998;27:53-68.
9. Bigras J, Fournier A, McCrindle BW, et al. Functional cardiac disturbances related to chemotherapy independent of anthracydine use in children with neoplastic disease. Am J Cardiol 1995; 75:101-103.
10. Van der Does-van der Berg A, Veerman AJP, van Wering ER, et al. Childhood acute lymphoblastic leukemia in The Netherlands. J Pediatr Hematol Oncol 1998;5:125-139.
11. Bender KS, Shematek JP, Leventhal BG, et al. QT interval prolongation associated with anthracycline cardiotoxicity. J Pediatr 1984;105:442-444.
12. Larsen RL, Jakacki RI, Vetter VL, et al. Electro cardiographic changes and arrhythmias after cancer therapy in children and young adults. Am J Cardiol 1992;70:73-77.
13. Schwartz CL, Hobbie WL, Truesdell S, et al. Corrected QT interval prolongation in anthracycline-treated survivors of childhood cancer. J Clin Oncol 1993;11:1906-1910.
14. Brodsky M, Wu D, Denes P, et al. Arrhythmias documented by 24 hour continuous electrocardiographic monitoring in 50 male medical students without apparent heart disease. Am J Cardiol 1977;39:360-395.
15. Sobotka PA, Mayer JH, Baurernfeind RA. Arrhythmias documented by 24 hours continuous ambulatory electrocardiographic monitoring in young women without apparent heart disease. Am Heart J 1981;101:753-759.
16. Nagashima M, Matsushima M, Ogawa A, et al. Cardiac arrhythmias in healthy children revealed by 24-hour ambulatory ECG monitoring. Pediatr Cardiol 1987;8:103-108.
17. Sahn DJ, DeMaria A, Kiilo J, et al. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 1978;58:1072-1083.
18. Daniels O, Voogd PJ, Gussenhoven WJ, et al. Left ventricular inner dimensions in normal children. In: Sobotka MA, Anthracycline cardiotoxicity in children: an echocardiographic study. Thesis, State University Leiden; 1991, p 97-100.
19. Rowland DG, Gutgesell HP. Use of mean arterial pressure for noninvasive determination of left ventricular end-systolic wall stress in infants and children. Am J Cardiol 1994;74:98-99.
20. Colan SD, Borow KM. Neumann A, et al. Left ventricular endsystolic wall stress-velocity of fiber shortening relation: a loadindependent index of myocardial contractility. J Am Coll Cardiol 1984;4:715-724.
21. Colan SD, Parness IA, Specak PJ, et al. Developmental modulation of myocardial mechanics: age-and growth-related alternations in afterload and contractility. JACC 1992;19:619-629.
22. Mirsky I, Pasipoularides A. Clinical assessment of diastolic function. Progr Cardiovasc Dis 1990;32:291-318.
23. Bu'Lock FA, Mott MG, Martin RP. Left ventricular diastolic dysfunction in children measured by Doppler echocardiography: normal values and relation with growth. Br Heart J 1995;73:334-339.
24. Bu'Lock FA, Mott MG, Oakhill A, et al. Left ventricular diastolic function after anthracycline chemotherapy in childhood: relation with systolic function, symptoms, and pathophysiology. Br Heart J 1995;73:340-350.
25. Hausdorf G, Morf G, Beron G, et al. Long-term doxorubicine cardiotoxicity in childhood: non-invasive evaluation of the contractile state and diastolic filling. Br Heart J 1988;60:309-315.
26. Marchandise B, Schroeder E, Bosly A, et al. Early detection of doxorubicin cardiotoxicity: interest of Doppler echocardiographic analysis of left ventricular filling dynamics. Am Heart J 1989; 118:92-98.
27. Henry WL, Ware J. Gardin JM, et al. Echocardiographic measurements in normal subjects. Circulation 1978;57:279-285.
28. Goldman L. Hashimoto B, Cook E. Comparative reproducibility and validity of systems for assessing cardiovascular functional class: advantages of a new specific activity scale. Circulation 1981;64:1227-1228.
29. Kitada M, Uheda K, Yasutake K, et al. Cardiac arrhythmias among school children and students. Jpn Circulation J 1979;43: 481-483.
30. Young D, Eisenberg R, Fish B, et al. Wenckebach atrioventricular block (Mobitz type I) in children and adolescents. Am J Cardiol 1977;40:393-398.
31. Brouwer J, editor. Autonomic control of the heart in cardiovascular disease: clinical applications of heart rate variability analysis. Thesis, State University Groningen; 1996.
32. Steinherz LJ, Steinherz PG, Tan CTC. Cardiac failure and dysrhythmias 6-19 years after anthracycline therapy: a series of 15 patients. Med Pediatr Oncol 1995;24:352-361.
33. Saul JP, Arai Y, Berger RD, et al. Assessment of autonomic regulation in chronic congestive heart failure by heart spectral analysis. Am J Cardiol 1988;61:1292-1299.
34. Hrushesky WJM, Fader DJ, Berestka JS, et al. Diminishment of respiratory sinus arrhythmia foreshadows doxorubicin-induced cardiomyopathy. Circulation 1991;84:697-707.
35. Postma A, Bink-Boelkens MTE, Beaufort-Krol GCM, et al. Late cardiotoxicity after treatment for a malignant bone tumor. Med Pediatr Oncol 1996;26:230-237.
36. Leandro J, Dyck J, Poppe D, et al. Cardiac dysfunction late after cardiotoxic therapy for childhood cancer. Am J Cardiol 1994;74: 1152-1156.
37. Nysom K, John K, Lipsitz SR, et al. Relationship between cumulative anthracycline dose and late cardiotoxicity in childhood acute lymphoblastic leukemia. J Clin Oncol 1998;16:545-550.
38. Krischer JP, Epstein S, Cuthbertson DD, et al. Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience. J Clin Oncol 1997;15: 1544-1552.
39. Hausdorf G. Late effects of anthracycline therpy in childhood: evaluation and current therapy. In: Bricker JT, Green DM, D'Angio GJ, editors. Cardiac toxocity after treatment for childhood cancer. New York: Wiley-Liss, Inc.: 1993. p 73-85.
40. Hausdorf G. Rettich TH, Keck EW, et al. Evaluation of left ventricular contractile performance for base-line stress-shortening data in man: comparison with pharmacological afterload challenge. Clin Cardiol 1988:11:764-770.
41. Kiewer SE, Goldberg SJ, Donnerstein RL, et al. Dobutamine stress echocardiography: a sensitive indicator of diminished myocardial function in asymptomatic doxorubicin-treated long-term survivors of childhood cancer. J Am Coll Cardiol 1992;19:394-401.
42. De Wolf D, Suys B, Maurus R, et al. Dobutamine stress echocardiography in the evaluation of late anthracycline cardiotoxicity in childhood cancer survivors. Pediatr Res 1996;39:504-512.